Menotropins - Biologic Drug Details

Summary for menotropins

Tradenames:	4
Patents:	2
Applicants:	3
BLAs:	4
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for menotropins

Recent Clinical Trials for menotropins

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Kuban State Medical University	Phase 2
Assiut University	N/A
Ferring Pharmaceuticals	Phase 3

See all menotropins clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for menotropins Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for menotropins Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ferring Pharmaceuticals Inc.	MENOPUR	menotropins	For Injection	021663		2014-04-08	Company disclosures
Ferring Pharmaceuticals Inc.	MENOPUR	menotropins	For Injection	021663		2016-06-20	Company disclosures

3) Low Certainty: US Patents for menotropins Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2033-03-11	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2029-05-13	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2029-01-29	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2035-10-09	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		1995-02-17	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2040-03-30	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2040-03-30	Patent claims search

International Patents for menotropins

Country	Patent Number	Estimated Expiration
Czech Republic	297937
Finland	863512
China	86106574
Hungary	9904031
Japan	2662390
Ukraine	49890
Norway	2000005

Supplementary Protection Certificates for menotropins

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C00214826/01	Switzerland		FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH
C990042	Netherlands		PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
SPC/GB99/045	United Kingdom		SPC/GB99/045: 20060829, EXPIRES: 20110828
99C0044	Belgium		PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
SZ 50/1999	Austria		PRODUCT NAME: INSULIN ASPART